ANDA 209467, held by Zydus Pharms. Succinylcholine Chloride.
As of Nov 16, 2026, ANDA 209467 (Succinylcholine Chloride), held by Zydus Pharms, was first approved by FDA on May 4, 2018, with 3 approved supplements and 0 published complete response letters.
Succinylcholine chloride injection is indicated in adults and pediatric patients: as an adjunct to general anesthesia to facilitate tracheal intubation to provide skeletal muscle relaxation during surgery or mechanical ventilation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 4, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Succinylcholine Chloride20MG/ML · injectable;injection | Succinylcholine Chloride | Rx |
| Feb 9, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 4, 2021 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 6, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| May 4, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters